JP6767392B2 - 複素環式化合物及び細菌感染の治療又は予防におけるその使用 - Google Patents

複素環式化合物及び細菌感染の治療又は予防におけるその使用 Download PDF

Info

Publication number
JP6767392B2
JP6767392B2 JP2017558028A JP2017558028A JP6767392B2 JP 6767392 B2 JP6767392 B2 JP 6767392B2 JP 2017558028 A JP2017558028 A JP 2017558028A JP 2017558028 A JP2017558028 A JP 2017558028A JP 6767392 B2 JP6767392 B2 JP 6767392B2
Authority
JP
Japan
Prior art keywords
mmol
oxo
diazabicyclo
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017558028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515504A (ja
Inventor
バルビオン ジュリアン
バルビオン ジュリアン
カラバノ オドレイ
カラバノ オドレイ
シャセ ソフィー
シャセ ソフィー
シュブルイユ フランシス
シュブルイユ フランシス
ルコワント ニコラ
ルコワント ニコラ
ルドゥサル ブノワ
ルドゥサル ブノワ
ル ストラ フレデリク
ル ストラ フレデリク
リシャール セバスチャン
リシャール セバスチャン
シモン クリストフ
シモン クリストフ
ボムシャイド ソフィー
ボムシャイド ソフィー
ブリア ジュリー
ブリア ジュリー
ブリエ ソフィア
ブリエ ソフィア
フェーブル ファビアン
フェーブル ファビアン
ル フラリック ジェラルディーヌ
ル フラリック ジェラルディーヌ
オリベイラ クリステル
オリベイラ クリステル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mutabilis SA
Original Assignee
Mutabilis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305701.3A external-priority patent/EP3091018A1/en
Application filed by Mutabilis SA filed Critical Mutabilis SA
Publication of JP2018515504A publication Critical patent/JP2018515504A/ja
Application granted granted Critical
Publication of JP6767392B2 publication Critical patent/JP6767392B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017558028A 2015-05-07 2016-05-06 複素環式化合物及び細菌感染の治療又は予防におけるその使用 Active JP6767392B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15305701.3 2015-05-07
EP15305701.3A EP3091018A1 (en) 2015-05-07 2015-05-07 Heterocyclic compounds and their use in preventing or treating bacterial infections
EP16305144 2016-02-08
EP16305144.4 2016-02-08
PCT/EP2016/060142 WO2016177862A1 (en) 2015-05-07 2016-05-06 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (2)

Publication Number Publication Date
JP2018515504A JP2018515504A (ja) 2018-06-14
JP6767392B2 true JP6767392B2 (ja) 2020-10-14

Family

ID=56083989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558028A Active JP6767392B2 (ja) 2015-05-07 2016-05-06 複素環式化合物及び細菌感染の治療又は予防におけるその使用

Country Status (13)

Country Link
US (1) US10183943B2 (enExample)
EP (1) EP3292125B1 (enExample)
JP (1) JP6767392B2 (enExample)
KR (1) KR102713561B1 (enExample)
CN (1) CN107580595B (enExample)
AU (1) AU2016257338B2 (enExample)
BR (1) BR112017023359A2 (enExample)
CA (1) CA2983674A1 (enExample)
CL (1) CL2017002803A1 (enExample)
MX (1) MX2017014080A (enExample)
RU (1) RU2741496C2 (enExample)
TW (1) TWI754613B (enExample)
WO (1) WO2016177862A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530690A (ja) * 2016-09-30 2019-10-24 ミュタビリスＭｕｔａｂｉｌｉｓ 複素環式化合物及び細菌感染症の予防又は治療におけるそれらの使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014135A1 (en) 2015-07-14 2017-01-19 Keith Edward Martin Surgical tool
EP3300736B1 (en) * 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
CN103649088B (zh) * 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
TW201343645A (zh) * 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
BR112014030266B1 (pt) 2012-06-04 2019-06-11 Elkimia Compostos imino como agentes de proteção contra radiações ultravioletas
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015059643A1 (en) * 2013-10-22 2015-04-30 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
CA2980085A1 (en) * 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530690A (ja) * 2016-09-30 2019-10-24 ミュタビリスＭｕｔａｂｉｌｉｓ 複素環式化合物及び細菌感染症の予防又は治療におけるそれらの使用
JP7089508B2 (ja) 2016-09-30 2022-06-22 ミュタビリス 複素環式化合物及び細菌感染症の予防又は治療におけるそれらの使用
JP2022097520A (ja) * 2016-09-30 2022-06-30 ミュタビリス 複素環式化合物及び細菌感染症の予防又は治療におけるそれらの使用

Also Published As

Publication number Publication date
RU2017135321A (ru) 2019-04-10
NZ736152A (en) 2024-09-27
CN107580595B (zh) 2020-09-18
CL2017002803A1 (es) 2018-05-11
AU2016257338B2 (en) 2020-03-05
CA2983674A1 (en) 2016-11-10
KR20180002650A (ko) 2018-01-08
AU2016257338A1 (en) 2017-10-26
CN107580595A (zh) 2018-01-12
TW201643165A (zh) 2016-12-16
MX2017014080A (es) 2018-07-06
WO2016177862A1 (en) 2016-11-10
TWI754613B (zh) 2022-02-11
RU2017135321A3 (enExample) 2019-08-13
US10183943B2 (en) 2019-01-22
US20180093985A1 (en) 2018-04-05
BR112017023359A2 (pt) 2018-07-17
JP2018515504A (ja) 2018-06-14
KR102713561B1 (ko) 2024-10-08
EP3292125A1 (en) 2018-03-14
RU2741496C2 (ru) 2021-01-26
EP3292125B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
JP7281527B2 (ja) ベータラクタマーゼ阻害剤化合物
CN107438614B (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
TW201609725A (zh) 作為抗癌劑之新穎三環化合物
AU2016257338B2 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
JP7089508B2 (ja) 複素環式化合物及び細菌感染症の予防又は治療におけるそれらの使用
EP3277686B1 (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections
TW201815390A (zh) 包含抗生素化合物及雜環化合物之組合物及其於預防或治療細菌感染之用途
CN107438610A (zh) 杂环化合物及它们在预防或治疗细菌感染中的应用
CN112513049A (zh) 杂环化合物及它们在预防或治疗细菌感染中的用途
EP3091018A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
EA044428B1 (ru) Соединения-ингибиторы бета-лактамаз
HK40002917B (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
HK1241877A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200917

R150 Certificate of patent or registration of utility model

Ref document number: 6767392

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250